glofitamab,epcoritamab,axicabtagene ciloleucel,tisagenlecleucel,Lisocabtagene Maraleucel
Roche,genmab,abbvie,gilead,novartis,bms
[]
 bad decision by the organizers. not enough data to support bispecifics yet.
Hematology fellow